Cytodyn Inc (CYDY)

[CTMedic]

DiscusDude,

Were the patients to have been equally assorted by age to treatment and placebo arms, Cytodyn would be in a different place.

The longhaulers/PACS trial seems well designed, with a slew of biochemical markers being evaluated, something missing from CD10 and 12.

I don’t know how/why Cytodyn has had no governmental support with previous trials. However, if the LH/PACS trial has unequivocally positive results, money will invariably come from Feds.

The direct cost and economic impacts of the LH/PACS are enormous and growing.

The science of leronlimab, despite doubts cast by some, is unassailable.

Period.

We need for Cytodyn management to cleanly plan and execute a trial, which seems to be the case with this trial.

All who claim that the CD12 results are worthless are deluding themselves (and attempting to delude us).

The mixed results with bad balance between treatment and placebo arms, as well as too few critical, doubtless was an unforced error.

As Covid continues to rage, vaccinations are paused, and OLE patients recover, leronlimab remains the hands-down best solution.